What does Lyxumia study of Sanofi SA (ADR) (NYSE:SNY) say

Posted by Nathan Alexander September 24, 2013 0 Comment 1732 views


Sanofi SA (ADR) (NYSE:SNY), a healthcare company based out of France, announced results from a sub-analysis which shows that Lyxumia is effective at lowering glucose and were great in patients with type 2 diabetes. According to the company, the result shows that Sanofi’s Lyxumia, when added to basal insulin, significantly reduced HbA1c levels in diabetic patients. It also observed that when Lyxumia was added to the basal insulin, resulted in the body weight reduction of the patients.

The study proves that Lyxumia is an effective post-prandial glucose lowering option that when added to basal insulin, improves HbA1c levels, said Sanofi SA (ADR) (NYSE:SNY).  In the sub-analysis, 496 patients were examined who were suffering from type 2 diabetes and inadequate glucose control. The addition of Sanofi’s Lyxumia to the basal insulin treatment reduced overall HbA1c levels among the patients, besides reducing the body weight and post-breakfast glucose levels.

Lyxumia (lixisenatide) is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) for treating patients with type 2 diabetes mellitus. The naturally-occurring peptide hormone Glucagon-like peptide-1 (GLP-1) is released within minutes after having a meal. In addition, Sanofi also said that the U.S. Food and Drug Administration (FDA) have approved NexGard for the treatment and prevention of flea infestations, and treatment and control of the American Dog tick, for one month.

NexGard is the first and only soft beef-flavoured chewable approved to kill both fleas and ticks. Available in four sizes, it will be a prescription-only product for oral administration to dogs and puppies. Merial, the animal health division of Sanofi said it will make NexGard available to veterinarians in time for the upcoming flea and tick season.

Sanofi SA (ADR) (NYSE:SNY) focuses on seven growth platforms, including diabetes solutions, innovative drugs, human vaccines, emerging markets, consumer healthcare, animal health, and the new Genzyme. The company has is present in European countries, North and Latin Americas, Asia, Africa and Middle East.


About Nathan Alexander

Nathan Alexander holds bachelor’s degrees in Journalism and European Studies from Boston University. Nathan reports round up the day’s business and financial market news and include keynote interviews with major business players and updates on Asian, European and US stock markets. He has interviewed heads of leading European banking institutions such as European Central Bank President Jean-Claude Trichet and HSBC Chairman Stephen Green, and CEOs from the business world including Microsoft founder Bill Gates, Virgin Chairman Sir Richard Branson and former Porsche President and CEO Dr Wendelin Wiedeking.

View all post by Nathan Alexander Visit author's website

Write Your Comment